Alexion CEO and CFO Depart

Alexion Pharmaceuticals Inc. outlined a shake-up of its top ranks on Monday, saying its chief executive and finance chief have left the company, effective immediately.

Connecticut-based Alexion said CEO David Hallal is resigning for personal reasons after 20 months in the position, to be replaced on an interim basis by board member and former AstraZeneca PLC CEO David Brennan. The company will launch a search for a permanent CEO.

CFO Vikas Sinah, meanwhile, will be succeeded by David Anderson, who left Honeywell International Inc. in 2014 after 11 years as CFO. Mr. Sinah, who spent 11 years at Alexion, is leaving to pursue other opportunities, the company said. In September, Mr. Vikas joined the board of drug-development firm Verona Pharma PLC.

Alexion is in the midst of an internal audit investigation related to a former employee's allegation of deceptive sales practices. The company said its committee hasn't found any facts that require the company to revise its financial results.

Write to Imani Moise at imani.moise@wsj.com

(END) Dow Jones Newswires

December 12, 2016 08:45 ET (13:45 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024